A Legislative History of the Federal Food, Drug, and Cosmetic Act and Its Amendments: TextU.S. Department of Health, Education, and Welfare, Public Health Service, Food and Drug Administration, 1979 - Cosmetics |
From inside the book
Results 1-5 of 100
Page 188
... sources of what in economic literature is referred to as " monopoly power . " These are the monopoly grant inherent in patents , the exceptionally large expenditures by the major companies on advertising and sales promotion , and the ...
... sources of what in economic literature is referred to as " monopoly power . " These are the monopoly grant inherent in patents , the exceptionally large expenditures by the major companies on advertising and sales promotion , and the ...
Page 190
... source data employed , the nature and the limitations of the various " computed unit production cost " figures presented by the subcommittee . This is necessary in order both to demonstrate the validity of the subcom- mittee's approach ...
... source data employed , the nature and the limitations of the various " computed unit production cost " figures presented by the subcommittee . This is necessary in order both to demonstrate the validity of the subcom- mittee's approach ...
Page 192
... source of information , used in cost estimates for products sold in capsule form , is found in the cost records of the Upjohn Co. for its tetracycline finishing and packaging operations . These records were made public in the ...
... source of information , used in cost estimates for products sold in capsule form , is found in the cost records of the Upjohn Co. for its tetracycline finishing and packaging operations . These records were made public in the ...
Page 193
... source of information , used in cost estimates for products sold in capsule form , is found in the cost records of the Upjohn Co. for its tetracycline finishing and packaging operations . These records were made public in the ...
... source of information , used in cost estimates for products sold in capsule form , is found in the cost records of the Upjohn Co. for its tetracycline finishing and packaging operations . These records were made public in the ...
Page 202
... Source of prices : 1959-60 American Druggist Blue Book . Per 1,000 Per tablet Cents $ 7.32 0.7 15.00 1.5 52.00 5.2 65.00 6.5 108.40 10. S The table above clearly illustrates Wyeth's cost disadvantage with respect to Carter . Carter ...
... Source of prices : 1959-60 American Druggist Blue Book . Per 1,000 Per tablet Cents $ 7.32 0.7 15.00 1.5 52.00 5.2 65.00 6.5 108.40 10. S The table above clearly illustrates Wyeth's cost disadvantage with respect to Carter . Carter ...
Other editions - View all
Common terms and phrases
ADMINISTERED PRICES ADMINISTERED PRICES-DRUGS advertising amended American Cyanamid American Home Products antibiotics Antitrust Antitrust and Monopoly appear application Association Aureomycin bill bottle brand name Bristol capsules Carter cents chart chemical chloramphenicol Chloromycetin chlorpromazine chlorpropamide Committee competition Corp corticosteroids cortisone Cosmetic countries Davis Decadron dexamethasone Diabinese discovery doctors Drug Administration drug companies drug industry drug manufacturers drug products efficacy erythromycin ethical drugs Federal firms Food and Drug foreign prices Hearings hospital Ibid insulin Journal Laboratories license Lilly margin medicine ment meprobamate Merck million MMSA National Office Orinase packaging Parke penicillin percent Pfizer pharmaceutical pharmacists pharmacy physician prednisolone prednisone prescribed prescription president Price to druggist prochlorperazine product patents production costs profit promotion reported retail royalty Schering Secretary selling Senator KEFAUVER side effects sold Squibb steroid subcommittee subsection Syntex Table tablets tetracycline thereof tion tolbutamide trade name United Upjohn
Popular passages
Page 475 - ... may obtain judicial review by filing in the United States court of appeals for the circuit wherein such person resides or has his principal place of business, or in the United States Court of Appeals for the District of Columbia Circuit, within sixty days after the entry of such order, a petition praying that the order be set aside in whole or in part.
Page 250 - That, as we enjoy great advantages from the inventions of others, we should be glad of an opportunity to serve others by any invention of ours; and this we should do freely and generously.
Page 475 - ... a petition with the United States court of appeals for the circuit wherein such person resides or has his principal place of business, for a judicial review of such order.
Page 475 - The judgment of the court affirming or setting aside, in whole or in part, any action of the Secretary shall be final, subject to review by the Supreme Court of the United States upon certiorari or certification as provided in section 1254 of Title 28, United States Code.
Page 447 - People of the same trade seldom meet together, even for merriment and diversion, but the conversation ends in a conspiracy against the public, or in some contrivance to raise prices.
Page 483 - Mr. President, I suggest the absence of a quorum. The PRESIDING OFFICER. The clerk will call the roll.
Page 12 - Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. The PRESIDING OFFICER. Without objection, it is so ordered.
Page 75 - Judiciary, or any duly authorized subcommittee thereof, is authorized under sections 134 (a) and 136 of the Legislative Reorganization Act of 1946, as amended, and in accordance with its jurisdictions specified by rule XXV of the Standing Rules of the Senate, to...
Page 476 - USC 1003). (d) After each such review, and at such other times as the Secretary may determine to be necessary or desirable, the Secretary shall cause to be compiled, published, and publicly distributed a list which shall list all revised official names of drugs designated under this section and shall contain such descriptive and explanatory matter as the Secretary may determine to be required for the effective use of those names.
Page 307 - CHLOROMYCETIN is a potent therapeutic agent and, because certain blood dyscrasias have been associated with its administration, it should not be used indiscriminately or for minor infections. Furthermore, as with certain other drugs, adequate blood studies should be made when the patient requires prolonged or intermittent therapy.